HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Neuroleptic malignant syndrome — Clinical Guidelines

Overview

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal adverse reaction associated with dopamine receptor antagonists, including both typical and atypical antipsychotics. It manifests with hyperthermia, muscle rigidity, altered mental status, and autonomic instability 1 17.

Diagnosis

Key Diagnostic Criteria: Hyperthermia (≥38°C), muscle rigidity, altered mental status, and autonomic dysfunction (diaphoresis, tachycardia, blood pressure fluctuations) 17.

Recommended Tests: Cerebrospinal fluid analysis typically normal; serum creatine kinase often elevated 17.

Grading: No standardized grading system universally accepted; clinical presentation severity often guides assessment 17.

Management

First-Line Treatments:

- Discontinue offending neuroleptic medication 1 17. - Supportive care including hydration, cooling measures, and monitoring vital signs 1 17.

Adjunctive Treatments:

- Dantrolene (initial dose 2.5 mg/kg IV, titrate as needed) 17. - Bromocriptine (initial dose 2.5-5 mg PO, titrate up to 15 mg/day) 17. - Electroconvulsive therapy (ECT) for refractory cases 13 21.

Special Populations

Pediatrics: NMS rare but reported in adolescents; risk factors include high-dose antipsychotics and concomitant medications 3 5.

Elderly: Increased susceptibility due to polypharmacy and comorbidities; careful monitoring essential 4.

Comorbidities: Patients with burns, cardiovascular issues, or recent infections may present unique challenges 2 14.

Key Recommendations

Prompt discontinuation of the offending antipsychotic is crucial in managing NMS (Evidence: Strong 1 17).

Initiate supportive care measures including temperature control and fluid management (Evidence: Strong 1 17).

Consider dantrolene or bromocriptine for refractory cases to manage muscle rigidity and hyperthermia (Evidence: Moderate 17).

Be vigilant in special populations, particularly pediatric and elderly patients, due to increased risk factors (Evidence: Moderate 3 4 5).

Monitor for complications such as rhabdomyolysis and hyperkalemia, especially in severe cases (Evidence: Moderate 22).

Use ECT cautiously; it may be effective in refractory cases but poses risks during active NMS (Evidence: Weak 13 21).

References

1 He J, Luo X, Li C, Zhong W, Sun M, Zhang C. Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database. Journal of affective disorders 2025. link 2 Ficarino HM, Caposole MZ, Noelle Davis S, N Krebsbach M, McGowin EF, Alexander KM et al.. Neuroleptic Malignant Syndrome: A Potential Etiology of Multisystem Organ Failure in a Burn Patient. The American surgeon 2022. link 3 León-Amenero D, Huarcaya-Victoria J. Neuroleptic malignant syndrome in children and adolescents: Systematic review of case reports. Revista Colombiana de psiquiatria 2021. link 4 Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M et al.. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta psychiatrica Scandinavica 2014. link 5 Henderson T. Neuroleptic malignant syndrome in adolescents: four probable cases in the Western Cape. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2011. link 6 Kozian R, Lesser K, Peter K. Dysarthric disorders associated with the neuroleptic malignant syndrome. Pharmacopsychiatry 1996. link 7 Staab WL. Neuroleptic malignant syndrome: critical factors. Critical care nurse 1994. link 8 Koponen HJ, Lepola UM, Leinonen EV. Neuroleptic malignant syndrome during remoxipride treatment. A case report. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1993. link90277-s) 9 O'Griofa FM, Voris JC. Neuroleptic malignant syndrome associated with carbamazepine. Southern medical journal 1991. link 10 Donnet A, Harle JR, Dumont JC, Alif Cherif A. Neuroleptic malignant syndrome induced by metoclopramide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 1991. link90048-x) 11 Rupreht J, Verkaaik AP, Erdmann W. Propofol safely used in a neuroleptic malignant syndrome patient. Anaesthesiologie und Reanimation 1991. link 12 Velamoor VR, Fernando ML, Williamson P. Incipient neuroleptic malignant syndrome?. The British journal of psychiatry : the journal of mental science 1990. link 13 Harland CC, O'Leary MM, Winters R, Owens J, Hayes B, Melikian V. Neuroleptic malignant syndrome: a case for electroconvulsive therapy. Postgraduate medical journal 1990. link 14 Ward MR, Corbett JA. Neuroleptic malignant syndrome with hypomania and mental retardation. Journal of mental deficiency research 1989. link 15 Madakasira S. Amoxapine-induced neuroleptic malignant syndrome. DICP : the annals of pharmacotherapy 1989. link 16 Green BH. The neuroleptic malignant syndrome and pneumomediastinum. The British journal of psychiatry : the journal of mental science 1989. link 17 Parikh AM, Camara EG. Neuroleptic malignant syndrome. American family physician 1988. link 18 Hosford I, Fernando N, Miller M. Neuroleptic malignant syndrome: case report and review. The New Zealand medical journal 1988. link 19 Shalev A, Hermesh H, Munitz H. The role of external heat load in triggering the neuroleptic malignant syndrome. The American journal of psychiatry 1988. link 20 Patterson JF. Neuroleptic malignant syndrome associated with metoclopramide. Southern medical journal 1988. link 21 Hermesh H, Aizenberg D, Weizman A. A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta psychiatrica Scandinavica 1987. link 22 Park RH, Jones H, O'Donnell JG, Griffen JS. The neuroleptic malignant syndrome. Scottish medical journal 1987. link 23 Lazarus A. The neuroleptic malignant syndrome: a review. Canadian journal of psychiatry. Revue canadienne de psychiatrie 1986. link 24 Moore A, O'Donohoe NV, Monaghan H. Neuroleptic malignant syndrome. Archives of disease in childhood 1986. link 25 Hughes JR. ECT during and after the neuroleptic malignant syndrome: case report. The Journal of clinical psychiatry 1986. link

Neuroleptic malignant syndrome